4/24/2025

Janusmed sex and gender

Janusmed sex and gender – Lenalidomide

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Lenalidomide

Lenalidomide

Class : C!

Show all info

Print

Contact us

  1. Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1703-7.

  2. Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-675.

  3. Liang X, Shi H, Bi K, Feng S, Chen S, Zhao W et al. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1. Sci Rep. 2024;14(1):2577.

  4. Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159(2):154-63.

  5. Lenalidomide Krka. Summary of Product Characteristics. European Medicines Agency [updated 2024-07-01, cited 2024-11-28]

  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1703-7.
  2. Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-675.
  3. Liang X, Shi H, Bi K, Feng S, Chen S, Zhao W et al. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1. Sci Rep. 2024;14(1):2577.
  4. Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159(2):154-63.
  5. Lenalidomide Krka. Summary of Product Characteristics. European Medicines Agency [updated 2024-07-01, cited 2024-11-28]
  6. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]